Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2002

View Archived Issues

Propecia significantly reduces hair loss, restores hair growth in men with androgenic alopecia

Bivalirudin reduces both thrombotic and bleeding complications in acute coronary syndromes

Pharmacological and pharmacokinetic profile of a new NK3 receptor antagonist

Peripheral COMT inhibitor with optimal properties designed at BIAL

First metabolic drug targets screened in Bayer/CuraGen alliance

Regeneron Q4 and year-end 2001 report

Quintiles and Kos sign commercialization agreement for Advicor and Niaspan

Cyproheptadine as effective as propranolol for neuroleptic-induced akathisia

Approvable letter received for use of Altocor in hypercholesterolemia

Amgen's Neulasta approved for febrile neutropenia

Guilford seeks expansion of indications for Gliadel in Europe

Zometa receives positive opinion for treatment of cancer-related bone metastases

SIGA Technologies' vaccine delivery system completes two clinical trials

Hybrigenics and Mindsense collaborate on biomarkers and drug targets for depression

Infectious disease research collaboration expanded by Cetek and Cubist

Heterocycles under study at Pfizer as inhibitors of 15-lipoxygenase

AHP describes preparation of novel soluble pegylated rapamycin derivatives

Preclinical milestone reached for Crucell human anti-CD46 antibody

Cyclic peptides synthesized for treatment of staphylococcal infections

Chronic inflammation, bone damage attenuated by M-40403 in rat model of arthritis

Factor Xa-inhibitory lactams disclosed by Bristol-Myers Squibb

New compounds identified at City of Hope to inhibit the glycation of proteins

Inhibitors of factor Xa described in patent by Cor Therapeutics

Researchers at Oncopeptides identify melphalan-containing peptides with antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...